Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 24 results:
Author Title [ Type] Year Filters: Author is Makatsoris, Thomas [Clear All Filters]
Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO..
Ann Gastroenterol. 29(1), 18-23.
(2016). Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab..
Clin Colorectal Cancer. 18(4), e370-e384.
(2019). Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer..
Anticancer Res. 39(4), 2129-2138.
(2019). Bevacizumab in the treatment of breast cancer..
Cancer Treat Rev. 36(1), 75-82.
(2010). Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes..
BMC Cancer. 13, 49.
(2013). Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO)..
Ann Gastroenterol. 29(4), 390-416.
(2016). Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO..
Ann Gastroenterol. 29(1), 3-17.
(2016). Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO)..
Ann Gastroenterol. 29(2), 103-26.
(2016). Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study..
BMC Cancer. 13, 263.
(2013). EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab..
J Cancer Res Clin Oncol. 140(5), 737-48.
(2014). Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial..
PLoS One. 10(5), e0124612.
(2015). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012). Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer..
Anticancer Res. 30(10), 4325-33.
(2010). Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases..
PLoS One. 8(3), e58182.
(2013). Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer..
ESMO Open. 4(2), e000474.
(2019). The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab..
Clin Colorectal Cancer. 12(4), 267-274.e2.
(2013).
(2010).
(2015).
(2011).
(2014). Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG)..
World J Urol.
(2015).
(2009).
(2012).